Jennifer Dowling, NP
Payments from drug & device makers
Across 286 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$437
- AstraZeneca$370
- Lilly USA, LLC$363
- Antares Pharma, Inc.$335
- Johnson & Johnson$235
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,670100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $1,067 |
| AbbVie | 27 | $437 |
| AstraZeneca | 17 | $370 |
| Lilly USA, LLC | 24 | $363 |
| Antares Pharma, Inc. | 18 | $335 |
| Johnson & Johnson | 19 | $235 |
| Bayer | 16 | $231 |
| GSK | 10 | $178 |
| Merck | 11 | $168 |
| Amgen | 9 | $146 |
| Astellas Pharma US Inc | 8 | $144 |
| Sanofi-aventis U.S. LLC | 7 | $116 |
| Halozyme Inc | 5 | $105 |
| Pfizer | 6 | $96 |
| Novartis | 4 | $91 |
| Exact Sciences | 4 | $71 |
| Sumitomo Pharma America, Inc. | 2 | $58 |
| Dexcom, Inc. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Corcept Therapeutics | 2 | $38 |
| Boehringer Ingelheim | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Amylyx Pharmaceuticals, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Corium, LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 2 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$125
How this compares
$4,670 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 110 | $111,847 |
| OzempicSemaglutide | 85 | $82,210 |
| RybelsusSemaglutide | 48 | $49,228 |
| EliquisApixaban | 66 | $49,017 |
| TrulicityDulaglutide | 37 | $47,929 |
| FarxigaDapagliflozin Propanediol | 47 | $40,888 |
| JardianceEmpagliflozin | 42 | $31,057 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $29,322 |
| JanuviaSitagliptin Phosphate | 30 | $28,729 |
| VraylarCariprazine Hcl | 13 | $17,071 |
| LinzessLinaclotide | 20 | $15,692 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $13,994 |
| EntrestoSacubitril/Valsartan | 17 | $11,174 |
| MyrbetriqMirabegron | 14 | $8,991 |
| XareltoRivaroxaban | 12 | $6,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $363 | $159,776147 claims |
| Novo NordiskOzempic, Rybelsus | $1,067 | $131,438133 claims |
| PfizerEliquis | $96 | $49,01766 claims |
| AstraZenecaFarxiga, Symbicort | $370 | $45,78558 claims |
| MerckJanuvia, Janumet Xr | $168 | $42,72346 claims |
| AbbVieVraylar, Linzess, Synthroid | $437 | $35,80685 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $178 | $32,71958 claims |
| Boehringer IngelheimJardiance | $36 | $31,05742 claims |
| NovartisEntresto | $91 | $11,17417 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $8,99114 claims |
| Johnson & JohnsonXarelto | $235 | $6,54112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Alma
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.